Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 02
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
AbbVie Inc
ABBV
NYSE
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$262.82
2.89
1.11%
Dern. MÀJ: Oct 2, 4:29 PM
$263.04
3.11
1.2%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Dividendes
Comparer
Rapport sur les stocks
Privacy Manager
Dividende:
La date ex-dividende est le dans 13 jours
AbbVie Financials
AbbVie (ABBV) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
AbbVie Affirms FY2026 Adj EPS Guidance of $13.87-$14.07 vs $14.08 Est
AbbVie (NYSE:ABBV) affirms FY2026 Adj EPS guidance from $13.87-$14.07 to $13.87-$14.07 vs $14.08 analyst estimate..
Benzinga Newsdesk
PRO
AbbVie Affirms Q3 Adj EPS Guidance of $3.84-$3.88 vs $3.84 Est
AbbVie (NYSE:ABBV) affirms Q3 Adj EPS guidance from $3.84-$3.88 to $3.84-$3.88 vs $3.84 analyst estimate..
Benzinga Newsdesk
PRO
Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate
Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share
Benzinga Newsdesk
PRO
Conference Call: AbbVie Sees Q3 Adj EPS $3.84-$3.88 vs $3.84 Est; Sees Sales $17.200B vs $17.322B Est
AbbVie (NYSE:ABBV) is looking for Q3 Adj EPS of $3.84-$3.88 vs $3.84 analyst estimate. sees sales of $17.200 billion vs $17.322 billion analyst estimate.
Benzinga Newsdesk
AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat
AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance below analyst targets.
Evette Mitkov
PRO
CORRECTION: AbbVie Lowers FY2026 Adj EPS Guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 Est
AbbVie (NYSE:ABBV) lowers FY2026 Adj EPS guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 analyst estimate..
Benzinga Newsdesk
